Re: Additional Reports Of Exempt Distribution.

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

KOO-KOO2

Rank: Treasurer [?]

Points: 10634 [?]

Votes: 39 Score: 2.3 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Additional Reports Of Exempt Distribution.

in response to

Re: Additional Reports Of Exempt Distribution.

fuzzyjr

posted on Jun 05, 2024 08:46PM

"Is zenith subject to blackout periods/similiar rules etc as the TSX?"

Zenith is a public company so I don't see why it would not be subjected to similar rules as the TSX during a blackout period.

However, we can't be in a blackout period because Zenith just issued warrants to (most likely) insiders and friends vis a vis, exempt distribution and Resverlogix issued securities to insiders as reported on SEDI, on June 4, 2024.